MIACALCIN NASAL SPRAY 200 IU

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

CALCITONIN (SALMON SYNTHETIC)

Inapatikana kutoka:

NOVARTIS PHARMACEUTICALS CANADA INC

ATC kanuni:

H05BA01

INN (Jina la Kimataifa):

CALCITONIN (SALMON SYNTHETIC)

Kipimo:

200UNIT

Dawa fomu:

SPRAY

Tungo:

CALCITONIN (SALMON SYNTHETIC) 200UNIT

Njia ya uendeshaji:

NASAL

Vitengo katika mfuko:

2 SPRAY BOTTLES

Dawa ya aina:

Prescription

Eneo la matibabu:

PARATHYROID AND ANTIPARATHYROID AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0111011001; AHFS:

Idhini hali ya:

CANCELLED POST MARKET

Idhini ya tarehe:

2013-10-01

Tabia za bidhaa

PRODUCT MONOGRAPH
PR
MIACALCIN* NS
Synthetic Calcitonin (Salmon)
Nasal Spray
200 IU/actuation
Bone Metabolism Regulator
Novartis Pharmaceutical Canada Inc.
Dorval, Québec
H9S 1A9
Control # 150460
Date of Revision:
November 1, 2011
Pr
MIACALCIN* NS is a registered trademark
MIACALCIN*NS (Synthetic Calcitonin) Page 2 of 35
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE
REACTIONS...................................................................................................
5
DRUG INTERACTIONS
.................................................................................................
10
DOSAGE AND ADMINISTRATION
.............................................................................
11
ACTION AND CLINICAL
PHARMACOLOGY............................................................
12
STORAGE AND STABILITY
.........................................................................................
15
SPECIAL HANDLING
INSTRUCTIONS.......................................................................
15
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 15
PART II: SCIENTIFIC INFORMATION
...............................................................................
16
PHARMACEUTICAL
INFORMATION.........................................................................
16
CLINICAL TRIALS
.........................................................................................................
16
DETAILED PHARMACOLOGY
.......................................................